OverviewChartProfileKey statisticsFinancialsNews
Derivatives
TraderScreen

IPSEN S.A. PORT. EO 1/  FR0010259150  /

Berlin
2024-06-06  9:50:02 PM Chg. 0.00 Volume Bid2024-06-06 Ask2024-06-06 Market Capitalization Dividend Y. P/E Ratio
122.80EUR 0.00% 0
Turnover: 0.00		 -Bid Size: - -Ask Size: - 10.29 bill.EUR 0.98% 15.76
GlobeNewswire 06-06 Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer   
GlobeNewswire 06-05 Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with...
GlobeNewswire 05-02 Ipsen appoints Keira Driansky as EVP, President of North America
GlobeNewswire 04-24 Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines...
GlobeNewswire 04-22 Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological di...
GlobeNewswire 04-02 Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid t...
GlobeNewswire 02-13 Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreat...
GlobeNewswire 02-08 Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
GlobeNewswire 2023-12-07 Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the trea...
GlobeNewswire 2023-12-07 Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid...
GlobeNewswire 2023-11-13 Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaki...
GlobeNewswire 2023-10-26 Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidan...
GlobeNewswire 2023-10-23 Ipsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome
GlobeNewswire 2023-10-03 Ipsen updates on QM-1114 regulatory process
GlobeNewswire 2023-09-04 Ipsen nominates Pascal Touchon to its Board of Directors as new independent director
GlobeNewswire 2023-09-01 Ipsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle Huguet
GlobeNewswire 2023-08-21 Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Caboza...
GlobeNewswire 2023-08-16 US FDA approves Ipsen’s SohonosTM (palovarotene) capsules, the first and only treatment for people w...
TeleTrader 2019-12-18 Ipsen's CEO leaves for FerGene
TeleTrader 2019-12-06 Ipsen stocks fall on new drug trials suspension
GlobeNewswire 2015-04-16 Active Biotech and Ipsen announce their decision to discontinue the development of tasquinimod in pr...
GlobeNewswire 2013-10-09 Active Biotech receives tasquinimod milestone payment from Ipsen for 10TASQ10 study
GlobeNewswire 2013-04-25 Active Biotech and Ipsen update the analysis plan for the 10TASQ10 trial evaluating tasquinimod in t...
GlobeNewswire 2012-12-10 Active Biotech and Ipsen announce completion of recruitment of tasquinimod clinical phase III study ...
GlobeNewswire 2012-10-03 Ipsen initiates a phase II "Switch maintenance" trial in metastatic castrate-resistant prostate canc...